Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2024 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Second Quarter 2024 Financial Results

Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product...